Insmed (INSM) Investor presentation summary

Strategic focus and therapeutic areas

• Pursues first- and best-in-class therapies across immunology, respiratory, inflammation, neuro, and rare diseases, with a diversified pipeline spanning all development phases.

• Key marketed products include brensocatib (BRINSUPRI) for bronchiectasis and ARIKAYCE for refractory MAC lung disease, with ongoing efforts to expand indications.

• Pipeline includes TPIP for multiple pulmonary indications and gene therapies for DMD, ALS, and Stargardt disease.

Financial performance and guidance

• Q1 2026 global net revenues for brensocatib reached $207.9M, with sequential growth of 44% over Q4 2025.

• Full-year 2026 revenue guidance for brensocatib is at least $1B, with ARIKAYCE expected to generate $450M–$470M.

• ARIKAYCE continues to show revenue growth in its eighth year post-launch, with Q1 2026 worldwide revenues of $98.1M.

Clinical development highlights

• Brensocatib achieved statistically significant reductions in pulmonary exacerbations in Phase 3 ASPEN study, supporting its approval and strong launch.

• ARIKAYCE demonstrated significant improvements in respiratory symptoms and culture conversion rates in MACLD, with plans to seek label expansion in the US and Japan.

• TPIP showed strong efficacy and safety in Phase 2 studies for PAH and PH-ILD, with significant improvements in pulmonary vascular resistance and exercise capacity.